Upadacitinib Dose Reduction Regimen in Elderly Patients with Atopic Dermatitis, Guided by Treat-to-Target Consensus Recommendations

Funding

This work was supported by grants from the National Natural Science Foundation of China (No.82373469), and the Natural Science Foundation of Fujian Province (No.2023J02017).

Conflict of interest

All authors have no conflicts of interest that are directly relevant to the content of this article.

Patient consent to publish

The requirement for informed patient consent was waived because of the anonymous nature of the data.

Code availability

Not applicable.

Author contributions

Dr Tong and Prof. Ji had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Zequn Tong, Xueting Zeng, Ting Gong, Chao Ji. Acquisition, analysis, or interpretation of data: Zequn Tong, Xueting Zeng, Fuchen Huang, Ying Zou, Zhenlan Wu, Huayu Chen, Jiawen Chen. Drafting of the manuscript: Zequn Tong, Xueting Zeng, Fuchen Huang, Ting Gong, Chao Ji. Critical review of the manuscript for important intellectual content: All authors. Statistical analysis: Zequn Tong, Xueting Zeng, Fuchen Huang, Ying Zou, Zhenlan Wu, Fa Chen. Obtained funding: Ting Gong, Chao Ji. Administrative, technical, or material support: Renwei Luo, Ting Gong, Chao Ji. Supervision: Ting Gong, Chao Ji.

IRB approval status

This study was approved by The Ethics Committee of the First Affiliated Hospital of Fujian Medical University (IRB [2022]007).

Informed consents

Written informed consent was obtained from patients to participate in this study.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Comments (0)

No login
gif